Tags

Type your tag names separated by a space and hit enter

Conivaptan: a selective vasopressin antagonist for the treatment of heart failure.
Expert Rev Cardiovasc Ther. 2006 Jan; 4(1):17-23.ER

Abstract

Heart failure commonly manifests as a syndrome of salt and water retention. Arginine vasopressin plays an important role in volume homeostasis and may contribute to this syndrome seen in heart failure patients. Recently, a number of agents have been developed that antagonize the effects of vasopressin. Conivaptan, which is a dual antagonist of the V1a and V2 receptor, has shown promise in animal studies and in small scale human trials as a potential therapeutic option for the treatment of acute and chronic heart failure. Further large studies are being conducted, which may confirm the benefits of conivaptan and other vasopressin antagonists in heart failure patients.

Authors+Show Affiliations

Schwarz ER
Division of Cardiology, Department of Internal Medicine, The University of Texas Medical Branch School of Medicine, Galveston, TX 77555-0553, USA. erschwarz@utmb.edu
Sanghi P
No affiliation info available

MeSH

AnimalsAntidiuretic Hormone Receptor AntagonistsArginine VasopressinBenzazepinesClinical Trials as TopicHeart FailureHumansReceptors, Vasopressin

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16375624

Citation

Schwarz, Ernst R., and Pramod Sanghi. "Conivaptan: a Selective Vasopressin Antagonist for the Treatment of Heart Failure." Expert Review of Cardiovascular Therapy, vol. 4, no. 1, 2006, pp. 17-23.
Schwarz ER, Sanghi P. Conivaptan: a selective vasopressin antagonist for the treatment of heart failure. Expert Rev Cardiovasc Ther. 2006;4(1):17-23.
Schwarz, E. R., & Sanghi, P. (2006). Conivaptan: a selective vasopressin antagonist for the treatment of heart failure. Expert Review of Cardiovascular Therapy, 4(1), 17-23.
Schwarz ER, Sanghi P. Conivaptan: a Selective Vasopressin Antagonist for the Treatment of Heart Failure. Expert Rev Cardiovasc Ther. 2006;4(1):17-23. PubMed PMID: 16375624.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Conivaptan: a selective vasopressin antagonist for the treatment of heart failure. AU - Schwarz,Ernst R, AU - Sanghi,Pramod, PY - 2005/12/27/pubmed PY - 2006/8/4/medline PY - 2005/12/27/entrez SP - 17 EP - 23 JF - Expert review of cardiovascular therapy JO - Expert Rev Cardiovasc Ther VL - 4 IS - 1 N2 - Heart failure commonly manifests as a syndrome of salt and water retention. Arginine vasopressin plays an important role in volume homeostasis and may contribute to this syndrome seen in heart failure patients. Recently, a number of agents have been developed that antagonize the effects of vasopressin. Conivaptan, which is a dual antagonist of the V1a and V2 receptor, has shown promise in animal studies and in small scale human trials as a potential therapeutic option for the treatment of acute and chronic heart failure. Further large studies are being conducted, which may confirm the benefits of conivaptan and other vasopressin antagonists in heart failure patients. SN - 1744-8344 UR - https://www.unboundmedicine.com/medline/citation/16375624/Conivaptan:_a_selective_vasopressin_antagonist_for_the_treatment_of_heart_failure_ DB - PRIME DP - Unbound Medicine ER -